US FDA approves GSK's Priorix vaccine

Monday, 06. June 2022 09:43

GlaxoSmithKline plc (GSK) announced on Monday that the United States Food and Drug Administration (FDA) has authorized Priorix (Measles, Mumps and Rubella Vaccine, Live) "for active immunization" and "the prevention of measles, mumps, and rubella (MMR) in individuals 12 months of age and older."

According to the company's press release, Priorix is currently authorized in more than 100 countries, including all European countries, Canada, Australia, and New Zealand, with over 800 million doses dispensed to date.

"We're proud to make Priorix available in the US for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases and to further strengthen offerings in our pediatric vaccine portfolio," said Judy Stewart, Senior Vice President and Head of US Vaccines, GSK.

Related Links: GlaxoSmithKline PLC
Baha Breaking News (BBN) / JG